Αναζήτηση Κλινικών

Αναζήτηση για:
Πόλη
Επιλογή Τμήματος

Εξωτερικά Ιατρεία

Πόλη
Επιλογή Τμήματος
Ημέρα εφημερίας

Συνδεδεμένοι χρήστες

Έχουμε 38 επισκέπτες συνδεδεμένους



UEHP News OCTOBER 2013


EUPOPEAN ECONOMY
The Second Economic Adjustment Programme for Greece- Fourth Review – April 2014


EUPOPEAN ECONOMY
The Second Economic Adjustment Programme for Greece- Second Review – May 2013


Health Professional Mobility in a Changing Europe
New dynamics, mobile individuals and diverse responses



LAW ADOPTED - MEPs back plans to boost joint assessment of medicines

4/10/2018

Dear UEHP members,

I would like to draw your attention on the fact that yesterday, the European Parliament approved its negotiating position on the proposal for a regulation on Health Technology Assessment (HTA), during the Plenary Session in Strasbourg . The proposal aims at strengthening cooperation between Member States in the field of HTA to end the current duplication of national clinical assessments, which results in delays in patient access to innovative care and financial and administrative burdens for health technology developers.

In particular, MEPs highlighted that there are many barriers to accessing medicine and innovative technologies in the EU, the main ones being the lack of new treatments for certain diseases and the high price of medicines, which in many cases do not have added therapeutic value.

Health professionals, patients and institutions need to know whether or not a new medicine or medical device is an improvement. Health technology assessments (HTA) therefore seek to identify their added value, comparing them with other products.

The new law aims to boost cooperation between member states in the field of HTA, by laying out the procedure for member states to carry out voluntary joint assessments. Provisions cover aspects such as rules for sharing data, setting up coordination groups, avoiding conflicts of interest among experts, and publishing the results of the joint work.

You can find more information, as well as the text adopted here: http://www.europarl.europa.eu/news/en/press-room/20180926IPR14444/meps-back-plans-to-boost-joint-assessment-of-medicines

REACTIONS: EFPIA, the European Federation of Pharmaceutical Industry and Associations, stated that the Parliament's position includes positive changes aimed at ensuring the quality of procedures and methodologies for joint clinical assessments. On the other hand, the inclusion of the possibility for Member States to carry out complementary evaluations appears to be critical, a provision that could lead to more uncertainty, complexity and additional obstacles to patients' access to new therapies.

Secretary General

UEHP – European Union of Private Hospitals

Avenue de la Joyeuse Entrée, 1  boite 11

B - 1040 Bruxelles  Belgium

 

Σύνδεση



Χρήσιμοι σύνδεσμοι

 

Δημοσιεύσεις